GW&K Investment Management LLC Acquires 91,054 Shares of AtriCure, Inc. $ATRC

Posted by Brian Himes on Jun 11th, 2026

GW&K Investment Management LLC increased its holdings in AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 10.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 952,089 shares of the medical device company’s stock after acquiring an additional 91,054 shares during the period. GW&K Investment Management LLC’s holdings in AtriCure were worth $37,665,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of ATRC. Aster Capital Management DIFC Ltd grew its holdings in shares of AtriCure by 197.1% in the third quarter. Aster Capital Management DIFC Ltd now owns 811 shares of the medical device company’s stock valued at $29,000 after acquiring an additional 538 shares in the last quarter. Geneos Wealth Management Inc. bought a new position in shares of AtriCure in the second quarter valued at approximately $37,000. Global Retirement Partners LLC bought a new position in shares of AtriCure in the fourth quarter valued at approximately $73,000. State of Wyoming bought a new position in shares of AtriCure in the fourth quarter valued at approximately $75,000. Finally, Comerica Bank grew its holdings in shares of AtriCure by 121.1% in the fourth quarter. Comerica Bank now owns 2,213 shares of the medical device company’s stock valued at $88,000 after acquiring an additional 1,212 shares in the last quarter. 99.11% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Karen Prange sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $28.65, for a total value of $85,950.00. Following the sale, the director owned 26,373 shares of the company’s stock, valued at $755,586.45. The trade was a 10.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 4.00% of the stock is currently owned by company insiders.

AtriCure Stock Up 0.8%

ATRC stock opened at $27.51 on Thursday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.18 and a current ratio of 4.29. The company has a market capitalization of $1.39 billion, a price-to-earnings ratio of -275.10 and a beta of 1.26. AtriCure, Inc. has a fifty-two week low of $25.36 and a fifty-two week high of $43.18. The stock has a fifty day moving average of $28.07 and a 200-day moving average of $33.14.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Wall Street Zen lowered AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Citizens Jmp lowered their price objective on shares of AtriCure from $60.00 to $52.00 and set a “market outperform” rating on the stock in a research report on Wednesday, February 18th. Citigroup reaffirmed an “outperform” rating on shares of AtriCure in a research report on Wednesday, February 18th. BTIG Research reaffirmed a “buy” rating and issued a $54.00 price objective on shares of AtriCure in a research report on Wednesday, February 18th. Finally, Weiss Ratings lowered shares of AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, AtriCure currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.71.

Get Our Latest Report on ATRC

AtriCure Company Profile

(Free Report)

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.